SLC5A2 and diabetes mellitus: Theguidelines stipulate that, unless contraindicated or intolerant, all patientswith HFrEF, regardless of diabetes status, should receive SGLT-2 inhibitors tomitigate the risk of hospitalization and death due to HF.